Table 3

Details of fully vaccinated and hospitalised individuals reported to the C19-GRA registry (n=22)

Age and sexComorbiditiesRheumatic diseaseMedications at the time of vaccinationMedications held for vaccinationMedications at the time of COVID-19 diagnosisVaccine received, time from last vaccination to SARS-CoV-2 infectionOutcome of hospitalisation*
31–40, FNoneSjogren’sHydroxychloroquine, methotrexate, BCDTUnknown, B cell depletion unknownHydroxychloroquine, methotrexate, BCDTPfizer-BioNTech, 61 daysNo supplemental oxygen
31–40, FLung disease, diabetes, chronic neurological/neuromuscular diseaseSLEBelimumab, mycophenolateNoBelimumab, mycophenolateModerna, 23 daysNo supplemental oxygen
31–40, FHypertension, BMI ≥30Inflammatory myopathyLeflunomide, BCDT, glucocorticoidNo, not B cell-depletedLeflunomide, BCDT, glucocorticoidUnknown, 30 daysSupplemental oxygen
31–40, FNonePsoriatic arthritisNoneTNFiPfizer-BioNTech, 170 daysNo supplemental oxygen
41–50, MHypertensionPsoriatic arthritisNoneNoneJanssen/Johnson & Johnson, 24 daysSupplemental oxygen
41–50, FLung diseaseRAAzathioprineUnknownAzathioprinePfizer-BioNTech, 55 daysSupplemental oxygen
41–50, FLung disease, BMI ≥30, kidney diseaseRAHydroxychloroquine, glucocorticoidNoTNFi, hydroxychloroquine, glucocorticoidUnknown, 120 daysInvasive ventilation/ECMO,
death
41–50, FHypertension, kidney disease, organ transplant recipient, immunodeficiency, BMI >30SLEMycophenolate, glucocorticoidNoMycophenolate, glucocorticoidPfizer-BioNTech, 14 daysSupplemental oxygen
51–60, FHypertensionRAIL-6 inhibitorUnknownIL-6 inhibitorAstraZeneca/Oxford, 30 daysSupplemental oxygen
61–70, MDiabetesInflammatory myopathyGlucocorticoidNoBCDT, glucocorticoidPfizer-BioNTech, 180 daysInvasive ventilation/ECMO,
death
61–70, MLung disease, hypertension, cardiovascular diseaseAxial spondyloarthritisBCDTB cell-depletedBCDTPfizer-BioNTech, 57 daysNon-invasive ventilation or high-flow oxygen devices, death
61–70, MLung disease, hypertension, cardiovascular disease, kidney diseaseANCA-associated vasculitisBCDTB cell-depletedBCDTModerna, 14 daysSupplemental oxygen
61–70, FLung diseaseRABCDT, glucocorticoidGC: no, B cell-depletedBCDT, glucocorticoidModerna, 78 daysInvasive ventilation, death
61–70, FNoneRAAbataceptNoAbataceptAstraZeneca/Oxford, 65 daysDischarged from hospital (no ventilation reported)
61–70, FDiabetes, BMI ≥30, hypertension, cardiovascular disease, kidney diseaseVasculitisGlucocorticoidNoGlucocorticoidPfizer-BioNTech, 150 daysSupplemental oxygen
61–70, FNoneRANoneMethotrexate, JAKiPfizer-BioNTech, 54 daysSupplemental oxygen
61–70, FNoneSystemic sclerosis, inflammatory myopathyAzathioprine/6-MP, BCDTB cell depletion unknownAzathioprine/6-MP, BCDTModerna, 16 daysDischarged from hospital (no ventilation reported)
71–80, MHypertension, cardiovascular disease, kidney diseaseInflammatory myopathyMycophenolateUnknownMycophenolatePfizer-BioNTech, 173 daysSupplemental oxygen
71–80, FLung diseaseRABCDTB cell-depletedBCDTJanssen/Johnson & Johnson, 38 daysSupplemental oxygen
>80, MLung disease, hypertension, cardiovascular diseaseVasculitisBCDT, glucocorticoidNo, B cell depletion unknownBCDT, glucocorticoidPfizer-BioNTech, 100 daysInvasive ventilation/ECMO,
death
>80, MCardiovascular disease, cancerPsoriatic arthritisGlucocorticoidYesUstekinumab, glucocorticoidPfizer-BioNTech, 140 daysNon-invasive ventilation or high-flow oxygen devices
>80, MHypertension, kidney diseaseVasculitisBCDTB cell depletion unknownBCDTModerna, 180 daysNon-invasive ventilation or high-flow oxygen devices
  • *Highest level of hospital treatment; if no discharge status, they were alive at discharge.

  • ANCA, Antineutrophil cytoplasmic antibody ; BCDT, B cell-depleting therapy; BMI, body mass index; C19-GRA, COVID-19 Global Rheumatology Alliance; ECMO, extracorporeal membrane oxygenation; F, female; GC, glucocorticoid; IL, interleukin; JAKi, Janus kinase inhibitor; M, male; 6-MP, 6-mercaptopurine; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TNFi, tumor necrosis factor inhibitor.